33 results about "Trisaccharide" patented technology

The invention relates to the technical field of sugar alcohol preparation, and discloses a preparation method of high-purity crystalline maltitol, which comprises the following steps: firstly, by taking corn starch milk as a raw material, preparing ultrahigh-content maltose syrup with the maltose content of more than or equal to 91%, the wheat triose content of less than or equal to 0.4% and the glucose content of less than or equal to 4% through an enzyme conversion method; carrying out hydrogenation reaction on the syrup by adopting a Raney nickel catalyst, and controlling the hydrogenation side reaction to be 2% or below, so as to obtain hydrogenated liquid with maltitol content of more than or equal to 88%; and then, a pigment separation procedure in a traditional process is omitted, and the hydrogenated liquid is directly subjected to decoloration, ion exchange, evaporation concentration, crystallization, centrifugation and drying treatment to finally prepare crystalline maltitol. According to the method, by screening a specific compound enzyme system and finely regulating the pH value and temperature control environment of a saccharification reaction system, the generation of maltose is effectively promoted, and side reactions such as excessive hydrolysis of glucose and reverse synthesis of trisaccharide are inhibited at the same time, so that the high-purity maltose syrup precursor is obtained.

The invention belongs to the technical field of biology, and particularly relates to Meyerozyma caribba XX2120, and the preservation number of the Meyerozyma caribba XX2120 is GDMCC No: 67777. The invention further relates to a preparation method of the Meyerozyma caribba XX2120. The strain is obtained by taking saccharomycetes X2120 as a starting strain, carrying out ARTP mutagenesis treatment and screening, has relatively strong acid resistance, relatively high salt stress resistance and certain alcohol resistance and aldehyde resistance, can effectively utilize monosaccharide, disaccharide and trisaccharide, has a wide utilization range on carbohydrate and has a relatively good utilization rate on inorganic nitrogen. Moreover, the strain can be used for producing mycoprotein through liquid fermentation by taking Luzhou-flavor distillers' grains as a raw material, and also can be used for performing solid fermentation on the Luzhou-flavor distillers' grains, so that the true protein content of the distillers' grains is increased, the nutritional value of the distillers' grains is improved, and the recycling of distillers' grain resources is effectively promoted.

A main object of the present invention is to provide a novel technique for activating T cell immune responses.SOLUTION: Solution to Problem The present inventors have found that the above problems can be solved by a compound represented by the general formula (I): wherein Sugar represents any monosaccharide, disaccharide, or trisaccharide; and R represents a hydrogen atom or an acyl group having 2 to 5 carbon atoms, or a salt thereof.SELECTED DRAWING: None

This invention relates to a composition for improving alcoholic liver damage, belonging to the field of health product technology. This application provides the use of rhodioloside and lactose-N-trisaccharide in the prevention and / or inhibition of alcoholic liver disease. This application also provides a composition of human lactose oligosaccharides and rhodioloside. The compositions described in this application can prevent the occurrence of alcoholic liver disease or inhibit its further deterioration. This application provides a green, safe, and healthy composition, offering an ideal composition for protecting human health.

The invention relates to the technical field of gene engineering, and particularly discloses a chitinase truncated body, a recombinant expression vector thereof, and a construction method and application of engineering bacteria. The chitinase truncated body is Cq181NC, the amino acid sequence of the Cq181NC is as shown in SEQ ID NO: 1, and the nucleotide sequence for coding the chitinase is as shown in SEQ ID NO: 2. According to determination, the chitinase truncation provided by the invention has the advantages that the specific enzyme activity is obviously improved by 1.8 times compared with that of a wild type, the chitinase truncation is high in environmental change tolerance, and the thermal stability of the chitinase truncation is still 1.43 times that of the wild type (incubation is performed for 8 hours at 35 DEG C). More importantly, the spectrum of the enzymolysis product is changed: the wild type is mainly disaccharide and shows a typical excision enzyme mode; and the truncated Cq181NC generates a plurality of oligosaccharides including monosaccharide, disaccharide, trisaccharide and hexasaccharide, shows double catalytic characteristics of endonuclease and exonuclease, and has a better application prospect.

The invention provides a production method for increasing the yield of maltose, which comprises the following steps: proportioning, liquefying and saccharifying, controlling the concentration of starch milk through proportioning, reducing the concentration of syrup, improving the flowability of a system, obtaining a liquefied liquid with a low DE value in the liquefying process, and simultaneously adjusting the pH values of different reaction steps, so that the yield of maltose is increased. Finally, after saccharification is completed, the ultrahigh malt syrup which is low in content of glucose, maltose trisaccharide, maltose trisaccharide or more and high in maltose content is obtained, and the highest maltose content can reach 93%.

The invention relates to a group B streptococcus oligoglycoprotein conjugate as well as a preparation method and application thereof, and belongs to the technical field of group B streptococcus vaccine development. Inactivated group A streptococcus C5a peptidase ScpA193 is used as a carrier and is connected with group B streptococcus oligosaccharide antigens to prepare the group B streptococcus-resistant oligosaccharide protein conjugate, and the oligosaccharide antigens are oligosaccharide trisaccharide derivatives, oligosaccharide pentasaccharide derivatives or oligosaccharide octasaccharide derivatives of group B streptococcus cell wall surface polysaccharides. The oligosaccharide protein conjugate prepared by the invention can simultaneously induce two types of antibodies with different target spots to synergistically aim at group B streptococcus, and is a compound vaccine. The vaccine has better applicability, can more effectively inhibit group B streptococcus, and is not limited by the problem of bacterial drug resistance caused by use of a large amount of antibiotics.

This invention discloses an antitumor natural drug composition based on Norway maple and its preparation method, relating to the field of biomedical technology. The compound is selected from at least one of the following structures: 3-O-[β-D-glucopyranosyl-(1→4)-[β-D-galactopyranosyl-(1→2)]]-β-D-glucopyranoside-21-O-acetyl-22-O-angeloyl yrutile alcohol, with the molecular formula C2. 55 H 86 O 23 This invention isolates a class of triterpenoid saponins with a rutinol skeleton from the bark of Norwegian maple, enriching the chemical composition library of maple species. The compounds contain unique oligosaccharide chains and diacyl substitution patterns at C-21 and C-22. One compound has a rare branched acyl group (3-hydroxy-4-methylhexanoyl) at C-21, while the other compound contains an arabinofuranose unit in its C-3 trisaccharide chain. These structural features are rare in natural products and demonstrate excellent structural novelty.

We provide a technology that can activate NRF2. [Solution] An NRF2 activator comprising one or more chondroitin sulfate oligosaccharides selected from (a) to (c) below as an active ingredient: (a) a disaccharide having a chondroitin sulfate structure (a disaccharide of CS), (b) a trisaccharide having two N-acetyl-D-galactosamine residues and a chondroitin sulfate structure (a trisaccharide of CS having two GalNac residues), (c) a tetrasaccharide having a chondroitin sulfate structure (a tetrasaccharide of CS). According to the present invention, NRF2 can be activated. This is expected to promote homeostatic reactions in the body, such as antioxidant reactions, anti-inflammatory reactions, and detoxification reactions, and contribute to maintaining and improving health. It is also expected to contribute to the prevention and improvement of various unhealthy conditions and diseases caused by oxidative stress, inflammation, and toxic chemicals.

Disclosed are a chemical synthesis method for Vibrio cholerae serotype O100 O-antigen oligosaccharide, and a use, belonging to the technical field of chemistry. The present invention uses three monosaccharide building blocks and five kinds of carboxylic acid derivative, and under the effects of solvent, temperature and neighboring group participation, through orthogonal protection, selective assembly and amide coupling, five Vibrio cholerae serotype O100 O-antigen oligosaccharide fragments are synthesized. Using the synthesized oligosaccharide fragments, combined with NMR analysis and carbohydrate chip technology, the absolute configuration and immunological function of the 3,5-dihydroxyhexanoyl group in the O-antigen trisaccharide are clarified, providing a theoretical basis for further structure-activity research and minimal antigen epitope screening. The present invention has promising applications in the synthesis of Vibrio cholerae glycoconjugate vaccines and the development of new drugs.

The invention belongs to the technical field of molecular markers, and particularly relates to an InDel molecular marker related to the content of quercetin 3-O-glucosyl rhamnosyl glucoside (Q-Glu-Rha-Glu) of a tea tree and application of the InDel molecular marker. The invention discloses an InDel molecular marker related (closely linked) to the content of quercetin triglucoside in a tea tree, the molecular marker is pRUG-InDel, and the nucleotide sequence of the molecular marker is SEQ ID No: 1. The method is not limited by tea tree planting areas, tree ages, seasons, organ or tissue aging degrees and the like, the tea tree original variety and the Pu'er tea variety are rapidly and efficiently distinguished, and the Q-Glu-Rha-Glu content potentials of different tea tree germplasm resources are predicted.

The present invention relates to a cell-free enzyme-catalyzed process for producing glycoproteins of general formula (I) from a lipid-linked oligosaccharide and a peptide. Further, said process includes the construction of the lipid-linked oligosaccharide from a mannose trisaccharide containing core structure. Particularly, the lipid-linked oligosaccharide is a high mannose-, complex-, or hybrid-type N-glycan.

The invention relates to a preparation method and application of Tianshan Pleurotus tuber-regium trisaccharide. The method comprises the following steps: crushing Tianshan Pleurotus tuber-regium, extracting and degreasing with ethanol, extracting degreased powder with hot water, concentrating, precipitating with ethanol, and taking a supernatant part to obtain crude oligosaccharide of the Tianshan Pleurotus tuber-regium; decoloring and removing small molecules through AB-8 macroporous adsorption resin, separating through a DEAE anion exchange resin column, and separating and purifying through an activated carbon-diatomite column and a Bio P-2 chromatographic column to obtain the Pleurotus tuber-regium trisaccharide. According to the present invention, the molecular weight is determined to be 504 Da, the total sugar content is 986.68-993.43 mg / g, the yield of the Pleurotus tuber-regium trisaccharide is 0.08-0.12%, and with the Pleurotus tuber-regium oligosaccharide crude product as the raw material, the monosaccharide analysis result shows that the Pleurotus tuber-regium trisaccharide mainly comprises glucose and galactose. The Tianshan fungus and Pleurotus tuber-regium trisaccharide obtained by the method provided by the invention has the efficacy of improving respiratory system inflammation.

This present disclosure provides various diamine centered poly(amino acid)-saccharide-lipid conjugates. In various embodiments, the conjugates can safely be used as water solubility or bioavailability enhancers. In one aspect, the present disclosure provides a conjugate having the structural formula wherein B is a residue of a compound having three or four available binding positions, e.g., an alkylene diamine; S is a saccharide, for example, a residue of a mono-, di- or trisaccharide group, in which each saccharide unit is a sugar, a sugar alcohol, an amino sugar or a sugar acid; L is a lipophilic carrier residue selected from fatty acid residues (for example, residues of lauric acid, myristic acid, linoleic acid, palmitic acid, oleic acid and elaidic acid), steroid acid and sterol residues, and residues of retinoids carotenoids, tocopherols, and tocotrienols; Q is a residue of ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol or hexaethylene glycol; P is a residue of a polyaminoacid homopolymer; R2 is a terminal group selected from H, methyl, ethyl and maleimide; D is a secondary group that is as defined above for L or is a methyl-capped poly(ethylene glycol) residue; and d is 0, or d is 1.

We provide oligosaccharides with a novel structure. [Solution] The solution is β-D-fructopyranosyl-(2→6)-β-D-glucopyranosyl-(1→6)-D-glucose represented by formula (I). The β-D-fructopyranosyl-(2→6)-β-D-glucopyranosyl-(1→6)-D-glucose represented by formula (I) is useful as a novel oligosaccharide and can be used in food and beverage compositions. In addition, it can be used in pharmaceuticals and functional foods that exhibit effects such as improving the intestinal flora as a prebiotic, regulating bowel function, stimulating the immune system, and anti-caries effects.

The invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the invention is in the technical field of culturing genetically engineered cells. The present invention describes: (i) a method for producing an oligosaccharide comprising milk-N-trisaccharide (LN3) or an oligosaccharide mixture comprising an oligosaccharide comprising LN3 by culturing a genetically modified cell comprising a transporter; and (ii) a genetically engineered cell for use in the method.

The present application provides a sulfonated trisaccharide and a preparation method thereof, the compound has drug activity, and can treat pulmonary arterial hypertension, inflammatory bowel disease and multiple sclerosis.

The present invention relates to a specific sugar fragment for the research and development of Vibrio cholerae vaccines. By means of a chemical synthesis method and sugar fragments related to the Vibrio cholerae O100 serotype O antigen trisaccharide, combined with sugar chip technology, the structure-activity relationship between different sugar fragments and the antigenicity thereof is evaluated at the molecular level. Sugar chip screening shows that 3-hydroxybutyryl is a key structural feature of the O antigen. The non-reducing terminal disaccharide carrying 3-hydroxybutyryl is the smallest potential antigen epitope. The disaccharide has a strong ability to bind to an antibody, has a simple structure, and can be used as a specific sugar fragment for the research and development of vaccines. Sugar-conjugated vaccines designed on the basis of the specific sugar fragment can solve challenges such as difficult culture of pathogenic bacteria and inhomogeneous sugar antigens in naturally extracted polysaccharide vaccines. The present invention has good application prospects in the research and development of Vibrio cholerae sugar-conjugated vaccines, the detection of infections, the development of novel drugs, etc.

This invention provides the use of a trisaccharide compound with a core structure of Glc(1→4)IdoA(1→4)GlcNS in the preparation of a drug for treating or preventing asthma. This compound can reduce lung inflammation in asthma model mice, reduce mucus production in the trachea, and effectively improve ventilation.

The application discloses an endolytic alginate lyase AlgC2m and application thereof. The biological enzyme is derived from a Paenibacillus-like bacterium enriched in a seaside soil sample. The application also discloses a recombinant expression vector and a recombinant host containing the alginate lyase AlgC2m gene. The application clones a new alginate lyase gene AlgC2m, which is 1320 bp in size, encodes 439 amino acids, and is classified into the PL-7 family. The similarity of the alginate lyase to alginate lyases in the same family is only 38%. The alginate lyase AlgC2m provided by the application has the function of degrading sodium alginate to prepare alginate oligosaccharide, and the main degradation product is unsaturated alginate disaccharide and trisaccharide, and has certain industrial application value.

The present disclosure provides PEG-saccharide-lipid conjugates centered around various diamines. In various embodiments, these conjugates can be safely used as water-soluble or bioavailability enhancers. In one aspect, the present disclosure provides a PEG-saccharide-lipid conjugate having the following structural formula. JPEG2026528703000080.jpg27170Here The number average value of m ranges from 2 to 10. S is a monosaccharide, disaccharide or trisaccharide group, and each sugar unit is a sugar, sugar alcohol, amino sugar or sugar acid. L is -C(O)-R 1 where R 1 is an alkanoyl or alkenoyl group having an average carbon number of 6 to 22, and / or a steroid acyl group. P is -(CH2-CH2-O)nR 2 where "n" has a number average value in the range of 5 to 50 (e.g., 8 to 45), and R 2 is hydrogen and / or an alkane and has a number average carbon number in the range of 0 to 4.

The present invention relates to spray-dried stable particles. The spray-dried stable particles comprise a water-soluble matrix containing approximately 5% to approximately 30% emulsifier, approximately 20% to approximately 75% filler, and 20% to approximately 50% mono-, di-, and trisaccharides, based on the total weight of the matrix; and at least one active component encapsulated within the matrix. The emulsifier is dextrin and the filler is potato maltodextrin.

The present invention provides a composition comprising: —at least one gel-forming hydrophobic carbohydrate ester or an analogue thereof based on mono-, di-, and tri-saccharides, or mixtures thereof; —at least one polymer; and —at least one solvent being mixable with water; wherein the composition is a ECell being a hydrophobic gel-depot having the ability to take up water by means of said at least one solvent being mixable with water and having the ability to self-expand by formation of water pores, channels, and / or cavities.

This invention belongs to the field of synthetic biology and discloses tetracycline compounds modified with a polysaccharide group at the C8 position, their biosynthetic methods, and applications. The tetracycline compounds with a polysaccharide group modification at the C8 position provided by this invention have a novel structure; the trisaccharide and hexasaccharide groups present at the C8 position are not found in known tetracycline natural products or tetracycline skeleton antibiotics. The biosynthetic method involves using a polysaccharide group derived from *Streptomyces rubrum*. ech Gene clusters, in which mis This invention expresses the gene cluster in the *Streptomyces micranthum* host, fully utilizing the different biosynthetic enzymes contained in two similar but different tetracycline natural product biosynthetic gene clusters to synthesize novel compounds that neither host bacterium can synthesize. These compounds exhibit significant inhibitory activity against *Staphylococcus aureus*, *Enterococcus faecalis*, and *Enterococcus faecium*. This invention provides new candidate compounds for the innovative development of tetracycline-based antibacterial drugs and is of great significance to the development of microbial drug resources.

This invention belongs to the field of bioengineering technology and discloses a recombinant Bacillus subtilis strain for producing lactoyl-N-trisaccharide, its construction method, and its application. The recombinant Bacillus subtilis strain uses Bacillus subtilis as the starting strain and selects strains with specific genomic features... amyE , lytG , lytC , srfAB , lytH , sigF , glmS , aprE , srfAC As the integration site, homologous recombination technology is used to directionally integrate genes related to lactoyl-N-trisaccharide synthesis and regulation into the aforementioned site. This invention, by directionally integrating genes related to lactoyl-N-trisaccharide synthesis and regulation into specific genomic sites in Bacillus subtilis and optimizing metabolic flux through transcriptional regulation systems, achieves a synergistic increase in product yield and strain biomass, significantly outperforming existing technologies.

This invention provides an oligosaccharide composition for improving neurodevelopment and functional disorders, comprising 6'-sialyl lactose and lactose-N-trisaccharide. The oligosaccharide composition provided by this invention can effectively inhibit the accumulation of Aβ protein, which leads to neuronal synaptic disorders, neuronal apoptosis, brain damage, and functional disorders. Therefore, the oligosaccharide composition provided by this invention can protect nerves and improve functional disorders. Furthermore, the oligosaccharide composition provided by this invention can also inhibit acetylcholinesterase activity, protect the normal development of cholinergic neurons, and increase neurotransmitter levels, thus benefiting the improvement of neurodevelopment, learning and memory abilities, and the improvement of behavioral coordination in infants and young children.

This invention discloses a heparin trisaccharide compound, its preparation method, and its applications, belonging to the field of compound preparation technology. The heparin trisaccharide compound is mainly prepared by the following method: linking a monosaccharide donor and a disaccharide acceptor through glycosylation, then reacting in a methanol / sodium methoxide system or a tetrahydrofuran / sodium hydroxide / water system, followed by sequential O-sulfonation, catalytic hydrogenation, and N-sulfonation post-treatment steps to obtain the heparin trisaccharide compound. This compound has a well-defined structure, a single component, and exhibits anti-angiogenic activity and anti-tumor potential.

The invention belongs to the technical field of bioengineering, and discloses a recombinant bacillus subtilis for producing lactyl-N-trisaccharide, a construction method and application, the recombinant bacillus subtilis is prepared by taking bacillus subtilis as an original strain, selecting amyE, lytG, lytC, srfAB, lytH, sigF, glmS, aprE and srfAC on a genome as integration sites, and preparing a recombinant bacillus subtilis strain; and directionally integrating lactyl-N-trisaccharide synthesis and regulation related genes to the sites through a homologous recombination technology. Lactyl-N-trisaccharide synthesis and regulation related genes are directionally integrated at the specific genome site of bacillus subtilis, and metabolic flux is optimized by combining a transcriptional regulation system, so that the product yield and the strain biomass are synergistically improved, and the method is obviously superior to the prior art.

The invention discloses a sargassum fusiforme alginate lyase IDDSAly7-2 as well as a preparation method and application thereof, and belongs to the field of bioengineering, and the amino acid sequence of the alginate lyase IDDSAly7-2 is as shown in SEQ ID No.2. The degradation products of the alginate lyase IDSAly7-2 mainly comprise unsaturated disaccharide and unsaturated trisaccharide, the degradation is thorough, and the uniformity of the products is good. Natural brown algae sargassum fusiforme can be specifically degraded, the degradation efficiency is remarkably superior to that of commercial cellulase, and oligosaccharide obtained through degradation has remarkable antioxidant activity. The method is suitable for large-scale preparation of alginate oligosaccharide in a low-temperature, alkalescent and low-salt system, and a new enzymology choice is provided for high-value utilization of sargassum fusiforme resources.